• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常规 68Ga-DOTATATE 正电子发射断层扫描在阑尾神经内分泌肿瘤切除术后的收益较低。

Routine Early 68Ga-DOTATATE Positron Emission Tomography Has Low Yield After Resection of Appendiceal Neuroendocrine Neoplasms.

机构信息

From the Departments of Nuclear Medicine.

Departments of Surgery.

出版信息

Pancreas. 2020 Aug;49(7):891-896. doi: 10.1097/MPA.0000000000001589.

DOI:10.1097/MPA.0000000000001589
PMID:32658069
Abstract

OBJECTIVES

Appendiceal neuroendocrine neoplasms (appNEN) generally carry a low recurrence risk. Ga-DOTATATE positron emission tomography (DOTA PET) is increasingly used as it is more sensitive than cross-sectional imaging. We hypothesize that early DOTA PET is unlikely to detect recurrent disease in patients with low-risk resected appNEN because of the delayed pattern of recurrence.

METHODS

Retrospective study (dual review) of patients undergoing DOTA PET 0 to 18 months after resected appNEN. The primary outcome was the proportion of scans demonstrating residual disease.

RESULTS

Forty-one patients were included (median age, 29 years; 63% female), most with small, low-grade appNEN. No scans (0%) showed residual/distant disease. Eight (20%) of 41 scans showed indeterminate findings requiring follow-up. Five (12%) scans were recommended for follow-up with modalities other than DOTA PET (vertebra, 3; thyroid; bone, 1 each). Three (7%) were recommended for follow-up with DOTA PET (all with indeterminate abdominal uptake). These 3 patients had no recurrent disease on follow-up.

CONCLUSIONS

The Ga-DOTATATE PET is of no value when performed in the first 18 months after resected appNEN. Although 20% of scans showed indeterminate findings, more than half did not require repeat DOTA PET. Despite advantages over cross-sectional imaging, DOTA PET is not recommended in staging after completely resected appNEN.

摘要

目的

阑尾神经内分泌肿瘤(appNEN)一般复发风险较低。与横断面成像相比,镓-DOTATATE 正电子发射断层扫描(DOTA PET)更敏感,因此越来越多地被应用。我们假设,由于复发模式延迟,早期 DOTA PET 不太可能检测到低风险切除的 appNEN 患者的复发病灶。

方法

回顾性研究(双次审查)对切除 appNEN 后 0 至 18 个月行 DOTA PET 的患者。主要结局是显示残留疾病的扫描比例。

结果

共纳入 41 例患者(中位年龄 29 岁;63%为女性),大多数为小、低级别 appNEN。没有扫描(0%)显示残留/远处疾病。41 次扫描中有 8 次(20%)显示需要随访的不确定结果。5 次扫描(3 次为椎体,1 次为甲状腺,1 次为骨骼)建议采用 DOTA PET 以外的方法进行随访。3 次扫描(均为腹部摄取不确定)建议用 DOTA PET 进行随访。这 3 例患者在随访中均未发现复发病灶。

结论

在切除 appNEN 后 18 个月内进行 Ga-DOTATATE PET 无价值。尽管 20%的扫描显示不确定结果,但超过一半的患者不需要重复 DOTA PET。尽管与横断面成像相比具有优势,但不建议在完全切除 appNEN 后进行分期使用 DOTA PET。

相似文献

1
Routine Early 68Ga-DOTATATE Positron Emission Tomography Has Low Yield After Resection of Appendiceal Neuroendocrine Neoplasms.常规 68Ga-DOTATATE 正电子发射断层扫描在阑尾神经内分泌肿瘤切除术后的收益较低。
Pancreas. 2020 Aug;49(7):891-896. doi: 10.1097/MPA.0000000000001589.
2
The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.68Ga-DOTATATE PET/CT 成像对神经内分泌肿瘤患者管理的影响:来自英国国家转诊中心的经验。
J Nucl Med. 2016 Jan;57(1):34-40. doi: 10.2967/jnumed.115.166017. Epub 2015 Oct 15.
3
Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.神经内分泌肿瘤复发:68Ga-DOTATATE PET/CT 诊断。
Radiology. 2014 Feb;270(2):517-25. doi: 10.1148/radiol.13122501. Epub 2013 Oct 28.
4
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.在血清降钙素水平升高的情况下,镓68 DOTATATE PET/CT在检测甲状腺髓样癌方面优于其他成像方式。
Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24. doi: 10.1967/s002449910163. Epub 2015 Feb 13.
5
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.胃肠胰神经内分泌肿瘤患者中 68Ga-DOTANOC 与 68Ga-DOTATATE PET/CT 的比较。
J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.
6
Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.68Ga-DOTATATE正电子发射断层扫描/计算机断层扫描用于检测胃肠胰神经内分泌肿瘤及未知原发部位的前瞻性研究
J Clin Oncol. 2016 Feb 20;34(6):588-96. doi: 10.1200/JCO.2015.64.0987. Epub 2015 Dec 28.
7
Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.神经内分泌肝脏转移瘤的评估:动态对比增强磁共振成像与正电子发射断层扫描/计算机断层扫描的比较。
Invest Radiol. 2014 Jan;49(1):7-14. doi: 10.1097/RLI.0b013e3182a4eb4a.
8
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.使用68Ga-DOTATATE(DOTA-DPhe1,Tyr3-奥曲肽)和18F-FDG联合PET/CT对神经内分泌肿瘤进行功能成像。
Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469.
9
The added value of Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin.镓-多柔比星-奥曲肽正电子发射断层扫描(Ga-DOTA-TATE-PET)相较于对比增强CT在检测神经内分泌起源的未知原发灶癌症(CUP)原发部位方面的附加价值。
Eur Radiol. 2017 Apr;27(4):1676-1684. doi: 10.1007/s00330-016-4475-3. Epub 2016 Jul 19.
10
Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?使用 68Ga-DOTA-NOC PET-CT 和 18F-FDG PET-CT 对胃肠胰神经内分泌肿瘤进行双示踪剂功能成像:竞争还是互补?
Clin Nucl Med. 2014 Jan;39(1):e27-34. doi: 10.1097/RLU.0b013e31827a216b.

引用本文的文献

1
Postoperative Ga-DOTATATE positron emission tomography has a low yield in incidental appendiceal neuroendocrine tumours.术后镓- DOTATATE正电子发射断层扫描在偶然发现的阑尾神经内分泌肿瘤中的检出率较低。
ANZ J Surg. 2024 Dec;94(12):2185-2188. doi: 10.1111/ans.19216. Epub 2024 Aug 23.
2
[Clinical significance of neuroendocrine tumors : Incidence, symptoms, diagnosis, stage, and prognostic factors and their influence on disease management].[神经内分泌肿瘤的临床意义:发病率、症状、诊断、分期、预后因素及其对疾病管理的影响]
Radiologie (Heidelb). 2024 Jul;64(7):536-545. doi: 10.1007/s00117-024-01315-y. Epub 2024 May 22.
3
Appendiceal Neuroendocrine Neoplasms: an Update for 2023.
阑尾神经内分泌肿瘤:2023 年的最新进展。
Curr Oncol Rep. 2024 Feb;26(2):114-120. doi: 10.1007/s11912-023-01484-4. Epub 2024 Jan 2.